These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29258858)

  • 1. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.
    Lee B; Hutchinson R; Wong HL; Tie J; Putoczki T; Tran B; Gibbs P; Christie M
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):241-252. PubMed ID: 29258858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.
    Passiglia F; Caglevic C; Giovannetti E; Pinto JA; Manca P; Taverna S; Listì A; Gil-Bazo I; Raez LE; Russo A; Rolfo C
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):259-268. PubMed ID: 29391205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
    Xiang Z; Yu Y
    Front Med; 2019 Feb; 13(1):24-31. PubMed ID: 30659409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
    Curigliano G
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
    Gevaert T; Montironi R; Lopez-Beltran A; Van Leenders G; Allory Y; De Ridder D; Claessens F; Kockx M; Akand M; Joniau S; Netto G; Libbrecht L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):216-227. PubMed ID: 29032188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.
    Zhang M; Yang J; Hua W; Li Z; Xu Z; Qian Q
    Front Med; 2019 Feb; 13(1):32-44. PubMed ID: 30680606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
    Li X; Song W; Shao C; Shi Y; Han W
    Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy: A need for peripheral immunodynamic monitoring.
    Wang W; Xia X; Wu S; Guo M; Lie P; He J
    Am J Reprod Immunol; 2018 Jun; 79(6):e12793. PubMed ID: 29288509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.
    Butterfield LH
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):12-15. PubMed ID: 28943324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours.
    Goswami M; Toney NJ; Pitts SC; Celades C; Schlom J; Donahue RN
    Clin Transl Med; 2024 Aug; 14(8):e1814. PubMed ID: 39162097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Older Adults: A Checkpoint to Palliation?
    Elias R; Odejide O
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e110-e120. PubMed ID: 31099630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery Strategies for Immune Checkpoint Blockade.
    Chen Q; Wang C; Chen G; Hu Q; Gu Z
    Adv Healthc Mater; 2018 Oct; 7(20):e1800424. PubMed ID: 29978565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.